Earnings ·
Entrada Therapeutics reported financial results for the quarter ended June 30, 2026
TRDAEntrada Therapeutics, Inc.
Entrada Therapeutics reported financial results for the quarter ended June 30, 2026. The company held $223.0 million in cash and marketable securities as of June 30, sufficient to fund operations into Q3 2027. Collaboration revenue was $0.9 million, while R&D expenses were $35.4 million and G&A expenses were $10.5 million, resulting in a net loss of $42.8 million. Clinically, ELEVATE-44-201 Cohort 2 enrollment is complete with data expected in Q1 2027, while ELEVATE-45-201 Cohort 2 dosing is ongoing at an increased dose of 10 mg/kg. The company plans to report ELEVATE-45-201 Cohort 1 data in October 2026 and ELEVATE-44-201 Cohort 1 open-label data by year-end 2026. Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular diseases.